# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-24-049107
Filing Date
2024-04-26
Accepted
2024-04-26 16:08:23
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | apls-2024-defa14a.htm | DEFA14A | 18445
2 | GRAPHIC | img182641356_0.jpg | GRAPHIC | 1256337
3 | GRAPHIC | img182641356_1.jpg | GRAPHIC | 135267
| Complete submission text file | 0000950170-24-049107.txt |  | 1934130

Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38276 | Film No.: 24883695
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)